MX2010009156A - Terapia de combinacion 238. - Google Patents

Terapia de combinacion 238.

Info

Publication number
MX2010009156A
MX2010009156A MX2010009156A MX2010009156A MX2010009156A MX 2010009156 A MX2010009156 A MX 2010009156A MX 2010009156 A MX2010009156 A MX 2010009156A MX 2010009156 A MX2010009156 A MX 2010009156A MX 2010009156 A MX2010009156 A MX 2010009156A
Authority
MX
Mexico
Prior art keywords
combination therapy
patient
kinase inhibitor
cancer
tor
Prior art date
Application number
MX2010009156A
Other languages
English (en)
Inventor
Juliane Jurgensmeier
Georgina Speake
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010009156A publication Critical patent/MX2010009156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona sistema de recipientes, equipos y métodos para soluciones de diálisis peritoneal (PD). Tal sistema, por ejemplo, incluye un primer compartimiento que contiene un agente osmótico de PD y un segundo compartimiento que contiene un agente amortiguador de PD. Los compartimientos mantienen sus respectivos contenidos separadamente entre sí para propósitos de transporte, almacenamiento y/o esterilización. Sin embargo, los compartimientos se pueden acoplar de manera fluida, de modo que sus respectivos contenidos se puedan combinar entre sí, por ejemplo, después de la esterilización de los agentes y antes de su introducción en el abdomen del paciente. La invención proporciona, en otros aspectos, tales sistemas, equipos y métodos que proporcionan estructuras protectoras que inhiben el rompimiento de un sello previamente entre el segundo compartimiento y una salida del sistema, antes de romper un sello entre el primero y segundo compartimientos.
MX2010009156A 2008-02-21 2009-02-20 Terapia de combinacion 238. MX2010009156A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3029908P 2008-02-21 2008-02-21
US4860508P 2008-04-29 2008-04-29
PCT/GB2009/050167 WO2009104019A1 (en) 2008-02-21 2009-02-20 Combination therapy 238

Publications (1)

Publication Number Publication Date
MX2010009156A true MX2010009156A (es) 2010-09-09

Family

ID=40552051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009156A MX2010009156A (es) 2008-02-21 2009-02-20 Terapia de combinacion 238.

Country Status (11)

Country Link
US (1) US20110028471A1 (es)
EP (1) EP2262504A1 (es)
JP (1) JP2011512395A (es)
KR (1) KR20100135754A (es)
CN (1) CN102014912A (es)
AU (1) AU2009215375A1 (es)
BR (1) BRPI0908100A2 (es)
CA (1) CA2715181A1 (es)
MX (1) MX2010009156A (es)
RU (1) RU2010138647A (es)
WO (1) WO2009104019A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101909433B1 (ko) 2011-12-02 2018-10-18 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 키나제 저해제의 부작용 저감제
JP2015520231A (ja) * 2012-06-25 2015-07-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ セジラニブを含んでいる眼科用局所医薬組成物
BR112016010716A8 (pt) 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
KR102594343B1 (ko) 2014-07-21 2023-10-26 노파르티스 아게 Cd33 키메라 항원 수용체를 사용한 암의 치료
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017031427A1 (en) * 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
CA3014674A1 (en) * 2016-02-15 2017-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods comprising fixed intermittent dosing of cediranib
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
US10467795B2 (en) * 2017-04-08 2019-11-05 Intel Corporation Sub-graph in frequency domain and dynamic selection of convolution implementation on a GPU
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
KR102371269B1 (ko) * 2020-03-11 2022-03-07 연세대학교 산학협력단 VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1167422C (zh) * 1999-02-10 2004-09-22 阿斯特拉曾尼卡有限公司 用作血管生成抑制剂的喹唑啉衍生物
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
CA2604983A1 (en) * 2005-03-17 2006-09-28 The Regents Of The University Of California Biomarker for sensitivity to mtor inhibitor therapy in kidney cancer
PL1954699T3 (pl) * 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
LT2057156T (lt) * 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
ES2398423T3 (es) * 2008-06-20 2013-03-19 Astrazeneca Ab Composiciones con y procedimiento para pirido[2,3-D]pirimidinas sustituídas con metilmorfolina

Also Published As

Publication number Publication date
AU2009215375A1 (en) 2009-08-27
KR20100135754A (ko) 2010-12-27
JP2011512395A (ja) 2011-04-21
EP2262504A1 (en) 2010-12-22
CN102014912A (zh) 2011-04-13
US20110028471A1 (en) 2011-02-03
WO2009104019A1 (en) 2009-08-27
BRPI0908100A2 (pt) 2015-10-06
CA2715181A1 (en) 2009-08-27
RU2010138647A (ru) 2012-03-27

Similar Documents

Publication Publication Date Title
MX2010009156A (es) Terapia de combinacion 238.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2009151910A3 (en) Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
SG10201811480WA (en) Therapeutic compounds and compositions
JO3134B1 (ar) مثبطات نشاط akt
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
UA104756C2 (uk) Сполуки ряду вініліндазолу
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
IN2012DN02081A (es)
MX357502B (es) Derivados de pirrolotriazinona.
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
AU316078S (en) Surgical tissue stimulator/locator
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
MX2011012505A (es) Piperidinas sustituidas.
UA107576C2 (ru) Замещенные пиперидины
EP2029615B8 (en) A process for the preparation of an oxaliplatin
MX2013015357A (es) Terapia de combinacion.
MX2010004259A (es) Tratamientos antitumorales mejorados.
HK1141436A1 (en) Axomadol for treating pain from arthritis